CLOVER HEALTH INVESTMENTS, CORP. /DE
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended September 30, 2026, as described below, one of the Company’s officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408(a) of Regulation S-K of the Securities Act).
On August 7, 2026, Andrew Toy, the Company’s Chief Executive Officer and a director, terminated his Rule 10b5-1 trading arrangement previously adopted on May 14, 2026. The arrangement was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and provided for the potential sale of up to 3,786,201 shares of the Company’s Class A common stock beginning no earlier than August 13, 2026, and ending no later than December 31, 2027, subject to specified market price conditions and other terms. No trades were executed under the arrangement prior to its termination.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.